RNS Press Release
For release: 24 November 2015
2015 Annual Report and Accounts & AGM Notification
Epistem Holdings Plc (LSE: EHP) ("Epistem" or "the Company"), the personalised medicine and biotechnology company, today gives notice that copies of its 2015 Annual Report and the Notice of the Annual General Meeting ("AGM") dated 23 November 2015 have been sent out to shareholders.
Copies of these documents can be found on the Company's website (www.epistem.co.uk).
The AGM will be held at 11am on Wednesday 16th December, 2015 at the offices of 41 Lothbury, London, EC2R 7HG.
For further details please contact:
Epistem Holdings Plc
Dr Ian Gilham: Chairman +44 (0)161 606 7258
John Rylands: Finance Director
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Tom Burt
Oliver Jackson
Consilium Strategic Communications
Chris Gardner / Laura Thornton +44 (0)203 709 5700
Notes to Editors
Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Genedrive® provides a major advance in molecular diagnostic testing by providing a rapid, low cost, simple to use 'Point of Care' device with high sensitivity and specificity for the diagnostics of infectious diseases and for use in patient stratification (genotyping). Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the India sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com